Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote In favor of Your #1 Compelling Female Producer - 2Fundamental Home Machines for Improved Solace in Summer
- 3Metropolitan Greatness: The 6 Urban areas for Quality Living in 2024
- 4Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
- 5Toyota Reports 2.3% Sales Drop as China Weakness Deepens
- Several killed in Ukraine and Russia after cross-border attacks
- Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- Dwayne ‘the Rock’ Johnson opens up about being the 'new guy' again — and why this moment feels like a new life
- Young Muslims in Germany feel left out of Mideast debate, experts say
- Figure out How to Use Your Nursing Abilities for Better Compensation
- Ways to track down the Right Criminal Legal counselor
- 'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- Why the UAE has incurred the wrath of Somalia
- The Force of Systems administration: Individual Examples of overcoming adversity
